Effect and Safety of Interferon for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Zhuang, Liping ^a,d   Zeng, Xiantao ^b   Yang, Zongguo ^c   Meng, Zhiqiang ^a,d  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b HUBEI UNIVERSITY   (China)

^c SHANGHAI PUBLIC HEALTH CLINICAL CENTER   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; DEMENTIA; DEPRESSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; FLU LIKE SYNDROME; HEPATITIS C VIRUS; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MENTAL DISEASE; META ANALYSIS; MYALGIA; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THYROIDITIS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; INTERFERONS; LIVER NEOPLASMS;

EID: 84884240286     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061361     Document Type: Article

References (50)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global Cancer Statistics. CA CANCER J CLIN 61: 69-90.
2. El-Serag HB, (2002) Hepatocellular carcinoma: An epidemiologic view. J Clin Gastrogenterol 35: S72-78.
3. Altekruse SF, Mcglynn KA, Reichman ME, (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27: 1485-1491.
4. Bruix J, Sherman M (2010) Management of hepatocellular carcinoma: An update. AASLD Practice Guidelines; Available: http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/HCCUpdate2010.pdf. Accessed 2013 March 26.
5. Nathan H, Schulick RD, Choti MA, Pawlik TM, (2009) Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 249: 799-805.
6. Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, et al. (2002) Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified? Ann Surg 236: 602-611.
7. Poon RTP, Fan ST, Wong J, (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232: 10-24.
8. Kianmanesh R, Regimbeau JM, Belghiti J, (2003) Selective approach to major hepatic resection for hepatocellular carcinoma in chronic liver disease. Surg Oncol Clin N Am 12: 51-63.
9. Said A, Wells J, (2009) Management of hepatocellular carcinoma. Minerva Med 100: 51-68.
10. Tang ZY (2001) Tang Zhao-you's Hepatocellular Carcinoma: Clinical. Shanghai, China: Shanghai Scientific and Technological Education Publishing House. 162p.
11. Park HC, Seong J, Tanaka M, Zeng ZC, Lim HY, et al. (2011) Multidisciplinary management of nonresectable hepatocellular carcinoma. Oncology 81: 134-140.
12. Kubo S, Nishiguchi S, Hamba H, Hirohashi K, Tanaka H, et al. (2001) Reactivation of viral replication after liver resection in patients infected with hepatitis. Annals of surgery 233: 139-145.
13. Jang JW, Choi JY, Bae SH, Kim CW, Yoon SK, et al. (2004) Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. Journal of Hepatology 41: 427-435.
14. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, et al. (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359: 1-10.
15. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA, et al. (2012) Pharmacology and therapeutic potential of interferons. Pharmacol Ther 135(1): 44-53.
16. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, et al. (1995) Randomized trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346: 1051-1055.
17. Liaw YF, (2004) Role of anti-viral therapy of HBV in the prevention of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 19: S128-S130.
18. Camma C, Licata A, Cabibbo G, (2005) Treatment of hepatitis C:critical appraisal of the evidence. Expert Opin Pharmacother 6: 399-408.
19. Shamliyan TA, MacDonald R, Shaukat A, Taylor BC, Yuan JM, et al. (2009) Antiviral therapy for adults with chronic hepatitis B:a systematic review for a National Institutes of Health Consensus Development Conference. Ann Int Med 150: 111-124.
20. Goldstein D, Laszlo J, (1998) The Role of Interferon in Cancer Therapy: A Current Perspective. Cancer Journal for Clinicians 38: 258-277.
21. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535.
22. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. Geneva,Switzerland pp. 4000-4514 p.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-16.
24. Therasse P, Eisenhauer EA, Verweij J, (2006) RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 42: 1031-9.
25. Higgins JPT, Green S, (2011) Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration Available: www.cochrane-handbook.org.
26. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, et al. (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336: 924-926.
27. Brozek J, Oxman A, Schünemann H, (2011) GRADEpro. [Computer program]. Version 3.6 for Windows.
28. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
29. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, et al. (2001) Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma: A randomized, controlled trial. Ann Int Med 134: 963-967.
30. Nishiguchi S, Tamori A, Kubo S, (2005) Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology 48: 71-75.
31. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, et al. (2002) Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 89: 418-422.
32. Lai CL, Wu PC, Lok AS, Lin HJ, Ngan H, et al. (1989) Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer 60: 928-933.
33. Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, et al. (1993) Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 17: 389-394.
34. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, et al. (2002) Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32: 228-232.
35. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, et al. (2000) Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 31: 54-58.
36. Chung YH, Song IH, Song BC, Lee GC, Koh MS, et al. (2000) Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-(alpha) for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 88: 1986-1991.
37. Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, et al. (2004) Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 100: 376-382.
38. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, et al. (2003) Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138: 299-306.
39. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, et al. (2006) Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44: 1543-1554.
40. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, et al. (2006) Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 132: 458-465.
41. Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, et al. (2007) A randomized,controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 245: 831-842.
42. Li M, Lu C, Cheng J, Zhang J, Cao C, et al. (2009) Combination therapy with transarterial chemoembolization and interferon-(alpha) compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 24: 1437-1444.
43. Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, et al. (2012) Long-term results of a randomized, observation-controlled, phase III Trial of Adjuvant Interferon alfa-2b in hepatocellular carcinoma after curative resection. Annals of Surgery 255: 8-17.
44. Dunk AA, Ikeda T, Pignatelli M, Thomas HC, (1986) Human lymphoblastoid interferon: In vitro and in vivo studies in hepatocellular carcinoma. J Hepatol 2: 419-429.
45. Wang L, Wu WZ, Sun HC, Wu XF, Qin LX, et al. (2003) Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg 7: 587-594.
46. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, et al. (2003) Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424: 516-523.
47. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD, (1998) How cells respond to interferons. Annu Rev Biochem 67: 227-264.
48. Gutterman JU, (1994) Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 91: 1198-1205.
49. Tomuleasa C, Soritau O, Fischer-Fodor E, Pop T, Susman S, et al. (2011) Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma. Hematol Oncol Stem Cell Ther 4: 60-66.
50. Zhuang PY, Zhang JB, Zhang W, Zhu XD, Liang Y, et al. (2010) Long-term interferon-α treatment suppresses tumor growth but promotes metastasis capacity in hepatocellular carcinoma. J Cancer Res Clin Oncol 136: 1891-1900.